Overview

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Global Blood Therapeutics